Proven Intelligence in Engineered Vector Analytics

Q: Why are standard analytical packages insufficient for IND-enabling studies of engineered AAV capsids?

Engineered AAV capsids possess novel biological properties that deviate from well-characterized natural serotypes. A standard analytical approach may fail to detect key attributes related to potency, purity, and safety. A tailored characterization strategy is required to understand unique receptor interactions, potential for altered immunogenicity, and ensure the vector’s stability and identity, which are foundational for a successful regulatory submission.

Q: How does capsid characterization influence the assessment of non-target tissue biodistribution?

The amino acid changes in an engineered capsid directly alter its surface chemistry and subsequent tissue interactions. Comprehensive characterization, including receptor affinity profiling, provides predictive data on where a vector is likely to accumulate. This allows for the design of more informative in vivo biodistribution studies in relevant animal models, minimizing the risk of unexpected toxicity and satisfying regulatory expectations for safety.

Q: What are the global regulatory expectations (FDA, MHRA) for a novel AAV vector’s CMC package?

Global regulatory bodies expect a comprehensive data package that demonstrates a deep understanding of the novel vector. This includes robust data on vector identity, purity, potency, and stability. Following harmonized international guidelines (ICH), the submission must definitively link the vector’s structural attributes to its functional performance and provide a clear scientific rationale for its design, supported by rigorous analytical data.

Executive Summary

Engineered AAV capsids require a bespoke analytical strategy to de-risk development and support regulatory submissions. This involves linking capsid-receptor affinity to in vivo performance and employing a matrix of orthogonal methods to build a comprehensive CMC data package. A tailored approach is fundamental for advancing novel vectors toward IND.

---

The utility of naturally occurring adeno-associated virus (AAV) serotypes in clinical applications is well-documented. Yet, limitations such as pre-existing neutralizing antibodies and suboptimal transduction of specific target tissues necessitate the design of engineered capsids. These novel vectors are developed to achieve enhanced tissue tropism, de-target organs like the liver to reduce toxicity, or improve transduction efficiency.

A tailored analytical and characterization strategy is not optional for these assets; it is fundamental to de-risking the entire development program. A one-size-fits-all testing template does not exist. The preclinical strategy must be adapted specifically to the vector’s design and intended clinical indication.

Linking Capsid Affinity to In Vivo Performance

Understanding the relationship between a novel capsid’s affinity for its target receptor and the receptor’s distribution in vivo is a key translational challenge. As demonstrated in studies of CNS-targeted vectors, quantifying capsid-receptor affinity provides a predictive framework for vector performance (PMID: 37199615). This data allows for the early identification of candidates with the highest probability of success and informs the design of subsequent IND-enabling toxicology studies.

Comparative analysis against established benchmarks is another pillar of a robust development plan. Evaluating engineered capsids like AAV3B alongside clinically validated serotypes such as AAV8 in nonhuman primate models provides definitive data on transduction efficiency for specific targets, such as the liver (PMID: 26412589). This head-to-head evaluation generates the necessary context for selecting the lead vector candidate to advance toward clinical trials.

Our scientific leadership and core operational team carry forward the track record that achieved a 100% successful IND rate since 2019, transitioning this expertise to Franklin Biolabs upon its formal launch in 2024. This deep institutional knowledge informs every aspect of vector design and characterization. A biotech sponsor noted this continuity: “We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate… The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption.”

A comprehensive characterization program for novel AAV capsids includes a matrix of orthogonal analytical methods. For a deeper look at program initiation and strategy, view our webinar on AAV project success [FBL-VID-03].

Analytical Domain	Methodologies	Purpose
Genome Integrity	Next-Generation Sequencing (NGS)	Confirms vector genome identity and sequence fidelity.
Capsid Content	Analytical Ultracentrifugation (AUC) or TEM	Quantifies the ratio of full (genome-containing) to empty capsids.
Purity & Aggregation	Size-Exclusion Chromatography (SEC-MALS)	Measures vector purity and detects the presence of aggregates.
Functional Potency	Custom Cell-Based Assays	Assesses the vector’s biological activity relevant to its mechanism of action.

This rigorous analytical framework provides the data required to build a robust CMC package for global regulatory submissions. These activities are performed within our GxP-compliant environments across more than 100,000 sq ft of dedicated laboratory space.

For more information on our full suite of capabilities, please see our main Vector | CMC | Analytics Services page.

---

---